Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Subjects With Relapsed/Refractory Large B-cell Lymphoma

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy for eligible subjects with relapsed/refractory (r/r) large B-cell lymphoma (LBCL).

Study Overview

• Status: Completed
• Conditions: Recurrent Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma; DLBCL Arising From Follicular Lymphoma
• Intervention / Treatment: Drug: Tisagenlecleucel; Drug: Axicabtagene ciloleucel; Drug: Lisocabtagene Maraleucel; Drug: Efineptakin alfa

Detailed Description

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL. The study consists of a Dose Escalation phase followed by a Dose Expansion phase.

In the Dose Escalation phase, subjects will be enrolled in 1 of 7 dose levels, starting with 60 µg/kg and up to 720 µg/kg. A dose schedule for an individual dose level will not be taken into expansion until the Dose Escalation phase has been completed or a maximum tolerated dose (MTD) has been determined, whichever occurs first.

In the Dose Expansion phase, up to 15 subjects will be enrolled and treated with the recommended dose identified in the Dose Escalation phase.

Up to 17- 42 subjects in the Dose Escalation phase, and up to 15 subjects in the Dose Expansion phase will be enrolled at approximately 20 study centers.

Treatment Plan:

NT-I7 (aka rhIL-7-hyFc, efineptakin alpha), Tisagenlecleucel (Kymriah®), Axicabtagene ciloleucel (Yescarta®), Lisocabtagene Maraleucel (Breyanzi®)

*CAR-T Therapy will be administered per manufacturer's recommendations and in accordance with Food and Drug Administration (FDA) prescribing guidelines and best institutional practices for standard of care use.

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City Of Hope
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University in St. Louis
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Subjects must meet all the following criteria for study entry:

1. Must be ≥18 years on the day of signing informed consent.
2. Be willing and able to provide written informed consent/assent for the study.
3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
4. Subjects should be eligible for CAR-T therapy respective to the current FDA-approved CAR-T label for Yescarta, Breyanzi, or Kymriah.

5. Subjects with histologically confirmed relapsed or refractory LBCL including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, DLBCL arising from follicular lymphoma, and primary mediastinal large B-cell lymphoma, must be eligible for standard of care (SOC) CD19 CAR T-cell Therapy.

   (a) Tumor tissue (fresh or archival) must have been tested to confirm the type of LBCL.

6. Subjects must have measurable disease by International Working Group (IWG) response criteria for lymphoma [Lugano classification (3)]

   1. Baseline fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scans must show positive lesions compatible with CT-defined anatomical tumor sites but will not be used in subsequent clinical decisions.
   2. A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable, and has clearly progressed.
   3. Subjects that received bridging therapy pre-lymphodepletion will be allowed for enrollment regardless of re-staging results (partial metabolic response [PMR] or complete metabolic response [CMR]), even if the lesion is not measurable per the criteria mentioned above.
   4. PET/CT scans done as SOC up to 28 days pre-lymphodepletion therapy will be allowed.

   All subjects whose scans are >28 days from lymphodepletion therapy will need a re-staging FDG-PET/CT) scan.

7. (This is a placeholder for inclusion criterion 7, which has been removed.)
8. Subjects must have a life expectancy of greater than or equal to 12 weeks per assessment from the enrolling physician.
9. Adequate organ and marrow function per institutional guidelines at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion.

The following laboratory parameters (9a-h) are recommendations. Labs outside of these ranges may be considered for inclusion after consultation with the medical monitor. Cytopenia resulting from disease or bridging therapy will not be considered exclusionary.

1. Hemoglobin ≥8.0 g/dL or ≥4.96 mmol/L
2. Absolute neutrophil count ≥1,000/µL
3. Platelets >50,000/µL
4. Total bilirubin ≤1.5 × institutional upper limit of normal (ULN) OR direct bilirubin ≤ULN for subjects with total bilirubin levels >1.5 × ULN, except subject with documented Gilbert's syndrome (>3 x ULN), who must have a baseline total bilirubin ≤ 3.0 mg/dL
5. aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) ≤2.5 × ULN (AST and/or ALT ≤5 × ULN for subjects with liver metastasis)
6. Alkaline phosphatase ≤2.5 × ULN (≤5 × ULN for subjects with documented liver involvement or bone metastases)
7. Creatinine clearance (CrCl) ≥30 mL/min as calculated per institutional standard.

8. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants 10. Female subjects who are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks; female subjects of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or to use dual methods of contraception for the duration of study treatment and for 90 days after NT-I7 injection, whichever is longer. Female subjects of childbearing potential (including women who have had a tubal ligation) must have a negative serum or urine pregnancy test within 72 hours prior to NT-I7 injection. If the urine test is positive, or cannot be confirmed as negative, a serum pregnancy test will be required.

   11. Electrocardiogram (ECG) demonstrating Fridericia's corrected QT interval (QTcF) < 500 ms. Patients with QTcF ≥ 500 ms will require clearance by a local cardiologist.

   Exclusion Criteria:

   Subjects meeting any of the following criteria are not eligible for enrollment in the study:

   1. In Dose Escalation phase: Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) post-CD19 CAR T-cell infusion. Note: Grade 1 or 2 CRS or ICANs must be completely resolved >3 days prior to NT-I7 injection
   2. In Dose Expansion phase: Grade ≥3 CRS or ICANS post-CD19 CAR T-cell infusion. Note: Grade 1 or 2 CRS or ICANS must be completely resolved >3 days prior to NT-I7 injection
   3. Pregnant, lactating or breastfeeding or expecting to conceive or father children within the study duration from screening through 120 days after the last dose of study treatment.
   4. This exclusion criteria has been removed and remains as a placeholder.
   5. Subjects with documented current central nervous system (CNS) involvement by lymphoma are to be excluded from study participation.

   6. Any concurrent chemotherapy or biologic or hormonal therapy for cancer treatment.

      Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable. In addition, local treatment (e.g., by local surgery or radiotherapy) of isolated lesions for palliative intent is acceptable beyond the dose-limiting toxicity (DLT) evaluation period with prior consultation and agreement with the medical monitor.

   7. Subjects who have autoimmune disease history for the past 2 years, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following are exceptions to this criterion:

      1. Subjects with vitiligo or alopecia.
      2. Subjects with type 1 diabetes mellitus.
      3. Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
      4. Psoriasis not requiring systemic treatment.
      5. NOTE: Diverticulitis that is not associated with inflammatory bowel disease is not considered exclusionary (e.g., subjects who do not have active diarrhea due to chronic diverticulitis).
   8. Have active and clinically relevant bacterial, fungal, viral, or TB infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required).
   9. Concurrent enrollment in another clinical study unless it is an observational (noninterventional) clinical study.
   10. Receipt of any conventional or investigational anticancer therapy, not otherwise specified above, within 30 days prior to NT-I7 injection.
   11. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Grade ≤1 with the exception of alopecia and laboratory values listed per the inclusion criteria. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by any of the investigational products may be included (e.g., hearing loss, peripheral neuropathy) after consultation with the medical monitor.
   12. Receipt of live, attenuated vaccine within 30 days prior to NT-I7 injection. Note: Subjects, if enrolled, should not receive live vaccine during the study and through 30 days after NT-I7 injection, whichever is longer. The administration of killed vaccines is permitted at any time.
   13. Has had an allogenic tissue/solid organ transplant or bone marrow transplant.
   14. Subjects for whom intramuscular therapy is contraindicated.
   15. Has clinically significant cardiac disease, including, but not limited to, any of the following:
   1. Uncontrolled atrial fibrillation
   2. Congestive Heart Failure New York Heart Association (NYHA) Class ≥2

   3. Or any of the following within 6 months prior to Baseline, Day 0 CAR-T administration:

      • Unstable angina
      • Myocardial infarction
      • Coronary artery bypass grafting
      • Coronary angioplasty
      • Coronary stenting
      • Clinically significant cardiac arrhythmia and/or conduction abnormality
   4. History of other clinically significant cardiac disease that, in the opinion of the Investigator or designee, is a contraindication to study treatment is also excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: NT-I7 after CAR-T (Kymriah, Yescarta, or Breyanzi) infusion; CAR-T infusion administered per standard of care at Day 0 followed by NT-I7 on Day 21.

Drug: Tisagenlecleucel; Administered as standard of care as described in the package insert on Day 0.; Other Names: Kymriah; Drug: Axicabtagene ciloleucel; Administered as standard of care as described in the package insert on Day 0.; Other Names: Yescarta; Drug: Lisocabtagene Maraleucel; Administered as standard of care as described in the package insert on Day 0.; Other Names: Breyanzi; Drug: Efineptakin alfa; NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.; Other Names: rhIL-7-hyFc; NT-I7

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence, Nature, and Severity of Adverse Events, Graded According to NCI CTCAE v5.0, Except for Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), Which Were Graded Based on ASTCT Guidelines	Treatment-Emergent Adverse Event (TEAE) is defined as an Adverse Event (AE) with an onset date on or after NT-I7 administration and on or before Day 100. A serious TEAE is defined as any AE that resulted in any of the following outcomes: death; a life-threatening AE; an AE that resulted in inpatient hospitalization or prolongation of existing hospitalization for ≥24 hours; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly/birth defect; important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.	From NT-I7 administration (Day 21) to Day 100
Incidence and Nature of DLTs	A Dose-Limiting Toxicity (DLT) is defined as any TEAE occurring within the first 21 days after NT-I7 administration that is considered to be at least possibly, probably, or definitely related to NT-I7 per the investigator, and that meets at least one of the protocol-defined non-hematologic or hematologic criteria.	From NT-I7 administration (Day 21) to Day 42
Potential Correlation of Dose Levels With Safety and Efficacy Parameters	The Recommended Phase 2 Dose (RP2D) was determined based on cumulative safety data and efficacy parameters (Objective Response Rate [ORR] and response rate at 6 months).	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of Duration of Response (DoR)	Duration of Response (DoR) for the responders is defined as the time from the first occurrence of a documented objective response (Partial Response [PR] or Complete Response [CR]) to the time of the first documented disease progression or death from any cause, whichever occurs first, per the Lugano classification as determined by the investigator. Only participants with a response were assessed. The median DoR was estimated using a Kaplan-Meier method.	Up to 24 months
Measurement of Progression-Free Survival (PFS)	Progression-Free Survival (PFS) is defined as the time from CAR T-cell administration to the first occurrence of disease progression or death from any cause, whichever occurs first. The Median PFS was estimated using the Kaplan-Meier method.	Up to 24 months
Measurement of Overall Survival (OS)	Overall Survival (OS) is defined as the time from CAR T-cell administration to death from any cause. The median OS was estimated using the Kaplan-Meier method.	Up to 24 months
Rates of Grade 3 and Higher Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)	The Grades of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are assessed based on the American Society for Transplantation and Cellular Therapy (ASTCT).	From NT-I7 administration (Day 21) to Day 100

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of expansion	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of maximum concentration (Cmax)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of time to maximum concentration (Tmax)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of persistence	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of terminal half-life (T1/2)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of last measured concentration (Clast)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Parameters of time of last measured concentration (Tlast)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Area under the curve for CAR T-cell expansion for days 0-21 (prior to NT-I7 administration)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Area under the curve for days 22-90 (after NT-I7 administration)	Up to 3 months
To make a preliminary assessment of PK parameters of Kymriah when administered NT-I7 post- Tisagenlecleucel therapy	Area under the curve for days 22-90 ( 3 months post Kymriah infusion)	Up to 3 months

Collaborators and Investigators

• Sponsor: NeoImmuneTech
• Investigators: Principal Investigator: John DiPersio, M.D., Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2021
• Primary Completion (Actual): December 18, 2024
• Study Completion (Actual): March 12, 2025

Study Registration Dates

• First Submitted: September 13, 2021
• First Submitted That Met QC Criteria: October 9, 2021
• First Posted (Actual): October 13, 2021

Study Record Updates

• Last Update Posted (Actual): August 10, 2026
• Last Update Submitted That Met QC Criteria: August 6, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma; Hemic and Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Antineoplastic Agents; Antineoplastic Agents, Immunological; axicabtagene ciloleucel; efineptakin alfa; tisagenlecleucel
• Other Study ID Numbers: NIT-112

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No